Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) Insider Sells 137 Shares of Stock

BeiGene, Ltd. (NASDAQ:BGNE) insider Titus B. Ball sold 137 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

BeiGene Stock Performance

Shares of BGNE traded up $2.93 on Thursday, reaching $191.58. 178,181 shares of the stock traded hands, compared to its average volume of 247,976. The stock’s 50-day moving average price is $169.96 and its 200-day moving average price is $161.41. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. The firm has a market cap of $18.56 billion, a price-to-earnings ratio of -25.31 and a beta of 0.59. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $213.83.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. The firm had revenue of $929.20 million during the quarter, compared to analysts’ expectations of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The company’s revenue for the quarter was up 56.1% compared to the same quarter last year. During the same quarter last year, the company earned ($3.64) earnings per share. Equities analysts forecast that BeiGene, Ltd. will post -5.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets raised its stake in shares of BeiGene by 7,724.1% in the fourth quarter. BNP Paribas Financial Markets now owns 59,307 shares of the company’s stock worth $10,697,000 after acquiring an additional 58,549 shares during the last quarter. Partners Capital Investment Group LLP bought a new stake in BeiGene during the 4th quarter worth about $2,762,000. Swedbank AB bought a new position in shares of BeiGene in the 1st quarter valued at about $2,596,000. AIA Group Ltd grew its position in shares of BeiGene by 38.9% during the 1st quarter. AIA Group Ltd now owns 18,497 shares of the company’s stock worth $2,893,000 after buying an additional 5,181 shares during the period. Finally, M&G Plc bought a new position in BeiGene in the first quarter valued at approximately $29,649,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. TD Cowen boosted their price objective on shares of BeiGene from $236.00 to $254.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Bank of America lowered their price target on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a report on Tuesday, July 9th. JPMorgan Chase & Co. increased their price objective on BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. Finally, Citigroup lifted their target price on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $239.81.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.